What do we need to know about the effectors of the immune response to be able to manipulate the immune system to ensure protection from viral pathogens? We need both predictors and correlates of protection. We need to distinguish between those individuals whose immune systems are competent to withstand a challenge, and those who require boosting or de novo vaccination. When designing vaccines, we need to know what epitope sequences should be included to elicit the most useful specificities, and what form of antigen will elicit the most critical effector function. Durable immune responses are essential, and thus identifying correlates of persistence and continued functionality is critical. In the case of new pandemics such as influenza, rapid deployment and dose sparing of vaccines may be needed. Therefore, it will be critical to identify which individuals in a susceptible population will mount an adequately robust response to limiting doses of vaccine, thus preserving stocks for those whose immune status requires subsequent boosts or higher doses of the vaccine.

The first step in defining immune parameters of protection is identification of the full repertoire of cells that comprise the response to infection. Prediction and enhancing immune responses requires identification of the cellular components that limit the immune response and the cells responsible for delivery of effector function ([Fig. 1](#fig1){ref-type="fig"}). We need to identify the bottlenecks in specificity or function that limit protective immunity to virus infection or successful vaccination. The conventional wisdom has been that CD8^+^ T cell responses play a major role in antiviral immunity. Although this remains true for many viruses, recent papers show that CD4^+^ T cells are also important, and in some cases are the major T cell component in the antiviral response ([@bib30]; [@bib26]; [@bib35]; [@bib5]; [@bib27]; [@bib31]; [@bib39]). The complexity of CD4^+^ T cell function, coupled with their broad specificity, has made detection of their contribution to vaccine responses and protective immunity relatively difficult. Unlike CD8^+^ T cells, which have reasonably well defined function and narrow antigen specificity, CD4^+^ T cells are tremendously complex. Therefore, the development of assays that will reveal the presence and full quantification of the relevant epitope-specific CD4^+^ T cells is a major challenge. It will also be important to identify the mechanisms responsible for their antiviral activity in the response. Collectively, these challenges have hampered efforts to acquire definitive evidence for the role of CD4^+^ T cells in anti-viral immunity. However, recent studies, including one in this issue by Zhou et al., demonstrate a critical role for CD4 T cells in protection from viral infection.

![**Many CD4 T cells expand in parallel in response to virus infection.** Recent advances now allow a full and unbiased assessment of this initial CD4 T cell repertoire to viral pathogens, typically composed of many peptide specificities, indicated by different colored symbols. As CD4 T cells expand in response to infection, they differentiate into subsets that possess distinct effector functions, including cytolysis, help for antibody responses, and cytokine production (three examples of subsets from the same original CD4 T cell precursor are shown here in alternate depths of color). Some of these functional subsets may be enriched for particular epitope specificities and others may be sequestered in infected tissues. Identification of the CD4 T cell population that limits protective immunity requires robust and sophisticated assays to isolate, quantify, and distinguish virus-specific CD4 T cells.](JEM_20121517_Fig1){#fig1}

Known activities of CD4^+^ T cells in antiviral immunity
========================================================

CD4^+^ T cells contribute a myriad of activities in protective immunity against viruses that are initiated by infection or by vaccination. These activities can be broadly separated into distinct categories that include recruitment of key lymphoid cell populations into secondary lymphoid tissue or sites of pathogen infection, provision of help for expansion or function of other effector cells, or offering direct effector function through production of cytokines or cell-mediated cytotoxicity. One key activity of CD4^+^ T cells is recruitment of other lymphoid cells: CD4^+^ T cells can promote engagement of CD8^+^ T cells with dendritic cells (DCs) in secondary lymphoid tissue ([@bib4]; [@bib7]), cause influx of lymphoid cells into draining lymph node ([@bib19]), and recruit innate or antigen-specific effectors to the site of viral replication ([@bib22]; [@bib32]; [@bib34]). Whether these CD4^+^ T cells are ever limiting in response to infection, and can thus serve as predictors of disease susceptibility, is not yet known.

The role of CD4^+^ T cell help in CD8^+^ T cell priming, effector function, and memory has been extensively studied in recent years ([@bib38]). Although such help may not be as critical for viruses that offer many CD8 epitopes ([@bib29]) and/or generate potent activating signals from DCs through strong Toll-like receptor engagement, it may be critical for pathogens that antagonize the immune response by down-regulating the activity of proinflammatory mediators. It is also likely to be essential for the development of memory CD8^+^ T cells that can be recalled upon challenge ([@bib40]). With chronic viral infections, the role and importance of CD4^+^ T cell help is even more profound. Under these conditions, CD8^+^ T cells rely on continued rounds of expansion for which CD4^+^ T cell cytokine production is critical ([@bib12]; [@bib13]; [@bib41]; [@bib3]).

That CD4^+^ T cell help is needed for high-affinity, neutralizing antibody responses by B cells has been known for decades, but more recent work has identified the follicular helper CD4^+^ T cells (Tfh) as the key subset that mediates this function ([@bib11]; [@bib17]). Recent identification of cells with Tfh lineage markers and functional activity in circulation of human subjects ([@bib10]; [@bib21]) raises the possibility that quantifying this subset may be useful as a biomarker for future vaccine responses, particularly if coupled with analyses of CD4 specificity. Finally, increasing evidence supports the view that CD4^+^ T cells have direct roles as effectors in antiviral immunity either through provision of key antiviral cytokines or through direct cytotoxicity ([@bib33]). Defining the complexity of CD4^+^ T cells has provided a pallet to dissect protective immunity in different human populations for distinct viral pathogens, but improved and more sophisticated assays are needed to reveal if the activities of CD4 T cells ever truly limit protective responses.

Complexity in assessing contribution of CD4^+^ T cells
======================================================

There are several major difficulties in assessing the contributions of CD4^+^ T cells to the control of virus infections. There is the breadth of the CD4^+^ T cell repertoire, which for influenza virus can include up to 100 distinct peptides specificities ([@bib9]). A recent study of human responses to vaccinia virus using a whole-proteome approach demonstrated that a mean of 39 open reading frames, each of which likely contain multiple peptide epitopes, were recognized by vaccinees ([@bib16]). Limited epitope sampling through use of a few favored peptides or limited antigens may prevent successful identification of the true correlates of protection as only some subsets of CD4^+^ T cells may participate in particular responses. For example, in HIV, subsets of lymphoid cells distinguish those that control infection versus those that do not ([@bib26]; [@bib35]). Recent comprehensive screening of a large cohort of infected subjects using peptides representing the entire proteome has revealed that differences in the CD4^+^ T cell immunodominance profile distinguished those who control the virus compared with those that progress ([@bib27]). The overall breadth of the response was inversely correlated with viral load, and the ratios of Gag-specific to Env-specific CD4^+^ T cells determined virus progression.

CD4^+^ T cell help for antibody responses is another situation that links CD4^+^ T cell specificity and functionality, because delivery of help for antibody responses normally requires that the B cell and CD4^+^ T cell recognize epitopes from the same antigen. Such help for antibody responses is restricted primarily to follicular helper cells ([@bib11]; [@bib17]). Tracking cells with irrelevant specificities or the wrong function may only add noise to assessments of CD4^+^ T cell functionality. Additionally, in humans, some CD4^+^ T cells may be invisible to experimentation because of restricted recirculation, and thus low abundance in peripheral blood. Finally, rapid and transient kinetics of the responses detected in peripheral blood after pathogen infection or vaccination ([@bib37]; [@bib20]; [@bib28]) may diminish detection and characterization of the responding CD4^+^ T cells in humans if sampled at the wrong time. Incomplete or inadequate consideration of these factors can lead to false-negative assessments of the role of CD4^+^ T cell responses to infection and vaccination, particularly in human subjects, in whom there are significant barriers to tissue sampling and response assessment.

In this issue, [@bib42] track CD4^+^ and CD8^+^ T cell responses over time during acute resolving hepatitis A virus (HAV) infection in chimpanzees. The studies were revealing because of the detailed and comprehensive nature of the study design. Frequent sampling of peripheral blood allowed simultaneous tracking of responses and viral gene expression, both during the acute phase (weeks 1--6) and long term. Sampling of serum, fecal material, and liver for HAV RNA allowed assessment of virus expansion, control, and rebound. The authors also sampled liver tissue biweekly for HAV-specific CD4^+^ and CD8^+^ T cells. CD4^+^ T cell specificity and functionality was probed using pools of HAV peptides representing the entire HAV genome in conjunction with intracytoplasmic staining for the key cytokines IL-2, TNF, IL-21, and IFN-γ. Surprisingly, these studies revealed few kinetic correlates between CD8^+^ T cell activity and control of viremia. Rather, early expansion of multifunctional CD4^+^ T cells that produced IL-2 and IL-21 IFN-γ and TNF was observed, with contraction after clearance of the virus. The highly differentiated phenotype of CD4^+^ T cells early in the response, lacking in the CD8 compartment, was noteworthy because of the role IFN-γ and TNF in inhibiting HAV replication. These coordinate kinetics of expansion of virus and CD4^+^ T cells in this primate model of infection suggested that the virus-specific CD4^+^ T cells contributed to ultimate control of virus in vivo.

This work echoes the conclusion of [@bib31] in a recent broad survey of acutely HIV-infected subjects, in which HIV CD4^+^ and CD8^+^ T cells were tracked over time using peptide pools representing the major virus proteins, in parallel with virus progression. Strikingly, early expansion and phenotype of CD4^+^ T cells, but not CD8^+^ T cells, specific for HIV were most closely associated with virus control. Moreover, expansion of granule-positive, HIV-specific cytotoxic CD4^+^ T cells was most tightly correlated with a positive outcome. Similarly, a recently reported study by [@bib39] explored the importance of CD4 T cells in protection from influenza in a challenge model in human subjects. As in the study by [@bib42], and those of [@bib31], multiple parameters were tracked over time, including viral titers in nasal washes, symptom scores, serological conversion to neutralizing antibody, and T cell responses that were elicited by large pools of synthetic peptides representing the whole virus proteome. Strikingly, the strongest association was a correlation between increased levels of preexisting influenza-specific CD4^+^ T cells with increased virus clearance and reduced symptom score. Additionally, early CD4^+^ T cell responses to virus infection were characterized by production of IFN-γ and cytotoxic activity. These results collectively suggest that preexisting memory CD4^+^ T cells can be rapidly mobilized for protection against novel virus strains, and that these T cells exert direct antiviral activity. This result is in agreement with mouse models of sequential infection for protection against pandemic challenge ([@bib1]) and surveys of human populations ([@bib15]; [@bib14]). The protection observed in [@bib39] can also be related to recent findings in animal models, showing that memory CD4^+^ T cells can promote rapid recruitment of innate effectors to the lung to establish an accelerated antiviral state ([@bib32]; [@bib34]). Additionally, recent studies in both murine influenza ([@bib5]), human cytomegalovirus, and HIV ([@bib30]; [@bib33]) suggest that CD4 T cell--mediated cytotoxicity of infected cells can play a critical function in viral clearance ([@bib2]; [@bib6]; [@bib31]). Thus, although the balance between CD4^+^ and CD8^+^ T cell--mediated effects are different for individual viruses, accumulating evidence points to the direct role of CD4^+^ T cells in protective immunity to many viruses.

The comprehensive analysis of CD4^+^ T cell responses by [@bib42], as well as the other recent studies highlighted in this minireview, provides provocative evidence of the essential role of CD4^+^ T cells in protection from virus infection in humans and primates. Coupled with mechanistic studies in animal models, advances in discovery ([@bib18]; [@bib29]; [@bib9]) and organization ([@bib36]) of T cell epitopes, increasingly sophisticated T cell phenotyping ([@bib24]; [@bib25]), and gene expression profiling ([@bib8]; [@bib23]) all provide roadmaps to select optimal vaccination strategies that elicit the preferred CD4^+^ T cells for the most effective protective immunity to virus infection.
